4/23/2024

Janusmed kön och genus

Janusmed kön och genus – Nexium HP

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Amoxicillin

Amoxicillin

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Philipson A, Sabath LD, Rosner B. Sequence effect on ampicillin blood levels noted in an amoxicillin, ampicillin, and epicillin triple crossover study. Antimicrob Agents Chemother. 1975;8:311-20.

  2. Andrew MA, Easterling TR, Carr DB, Shen D, Buchanan ML, Rutherford T et al. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther. 2007;81:547-56.

  3. Amimox (amoxicillin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-10-23, cited 2020-04-22]

  4. den Heijer CD, Donker GA, Maes J, Stobberingh EE. Antibiotic susceptibility of unselected uropathogenic Escherichia coli from female Dutch general practice patients: a comparison of two surveys with a 5 year interval. J Antimicrob Chemother. 2010;65:2128-33.

  5. den Heijer CD, Penders J, Donker GA, Bruggeman CA, Stobberingh EE. The importance of gender-stratified antibiotic resistance surveillance of unselected uropathogens: a Dutch Nationwide Extramural Surveillance study. PLoS One. 2013;8:e60497.

  6. McGregor JC, Elman MR, Bearden DT, Smith DH. Sex- and age-specific trends in antibiotic resistance patterns of Escherichia coli urinary isolates from outpatients. BMC Fam Pract. 2013;14:25.

  7. Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis. 2013;13:19.

  8. Badura A, Feierl G, Pregartner G, Krause R, Grisold AJ. Antibiotic resistance patterns of more than 120 000 clinical Escherichia coli isolates in Southeast Austria, 1998-2013. Clin Microbiol Infect. 2015;21(6):569e1-7.

  9. Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D, Zhang J, Bhattacharyya H, King EC, Hopkins RJ. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med. 2002;136(1):13-24.

  10. Frumkin K. Bacteriology of urinary tract infections in emergency patients aged 0-36 months. J Emerg Med. 2015;84(4):405-15.

  11. Korinek AM, Golmard JL, Elcheick A, Bismuth R, van Effenterre R, Coriat P et al. Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4,578 patients. Br J Neurosurg. 2005;19:155-62.

  12. Korinek AM, Baugnon T, Golmard JL, van Effenterre R, Coriat P, Puybasset L. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery. 2006;59:126-33; discussion 126-33.

  13. Chovel-Sella A, Ben Tov A, Lahav E, Mor O, Rudich H, Paret G et al. Incidence of rash after amoxicillin treatment in children with infectious mononucleosis. Pediatrics. 2013;131(5):e1424-7.

  14. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014;89:95-106.

  15. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol. 2010;53:1049-53.

  16. McNicholl AG, Molina-Infante J, Lucendo AJ, Calleja JL, Pérez-Aisa Á, Modolell I, Aldeguer X, Calafat M, Comino L, Ramas M, Callejo Á, Badiola C, Serra J, Gisbert JP. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial. Helicobacter. 2018;23(5):0.

  17. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Philipson A, Sabath LD, Rosner B. Sequence effect on ampicillin blood levels noted in an amoxicillin, ampicillin, and epicillin triple crossover study. Antimicrob Agents Chemother. 1975;8:311-20.
  2. Andrew MA, Easterling TR, Carr DB, Shen D, Buchanan ML, Rutherford T et al. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther. 2007;81:547-56.
  3. Amimox (amoxicillin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-10-23, cited 2020-04-22]
  4. den Heijer CD, Donker GA, Maes J, Stobberingh EE. Antibiotic susceptibility of unselected uropathogenic Escherichia coli from female Dutch general practice patients: a comparison of two surveys with a 5 year interval. J Antimicrob Chemother. 2010;65:2128-33.
  5. den Heijer CD, Penders J, Donker GA, Bruggeman CA, Stobberingh EE. The importance of gender-stratified antibiotic resistance surveillance of unselected uropathogens: a Dutch Nationwide Extramural Surveillance study. PLoS One. 2013;8:e60497.
  6. McGregor JC, Elman MR, Bearden DT, Smith DH. Sex- and age-specific trends in antibiotic resistance patterns of Escherichia coli urinary isolates from outpatients. BMC Fam Pract. 2013;14:25.
  7. Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis. 2013;13:19.
  8. Badura A, Feierl G, Pregartner G, Krause R, Grisold AJ. Antibiotic resistance patterns of more than 120 000 clinical Escherichia coli isolates in Southeast Austria, 1998-2013. Clin Microbiol Infect. 2015;21(6):569e1-7.
  9. Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D, Zhang J, Bhattacharyya H, King EC, Hopkins RJ. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med. 2002;136(1):13-24.
  10. Frumkin K. Bacteriology of urinary tract infections in emergency patients aged 0-36 months. J Emerg Med. 2015;84(4):405-15.
  11. Korinek AM, Golmard JL, Elcheick A, Bismuth R, van Effenterre R, Coriat P et al. Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4,578 patients. Br J Neurosurg. 2005;19:155-62.
  12. Korinek AM, Baugnon T, Golmard JL, van Effenterre R, Coriat P, Puybasset L. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery. 2006;59:126-33; discussion 126-33.
  13. Chovel-Sella A, Ben Tov A, Lahav E, Mor O, Rudich H, Paret G et al. Incidence of rash after amoxicillin treatment in children with infectious mononucleosis. Pediatrics. 2013;131(5):e1424-7.
  14. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014;89:95-106.
  15. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol. 2010;53:1049-53.
  16. McNicholl AG, Molina-Infante J, Lucendo AJ, Calleja JL, Pérez-Aisa Á, Modolell I, Aldeguer X, Calafat M, Comino L, Ramas M, Callejo Á, Badiola C, Serra J, Gisbert JP. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial. Helicobacter. 2018;23(5):0.
  17. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]
A A
A A

Klaritromycin

Klaritromycin

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C et al. Worldwide H pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010;19:409-14.

  2. Bluemel B, Goelz H, Goldmann B, Grüger J, Hamel H, Loley K et al. Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018. Clin Microbiol Infect. 2020;26(2):235-239.

  3. Coeman M, van Durme Y, Bauters F, Deschepper E, Demedts I, Smeets P et al. Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study. Ther Adv Respir Dis. 2011;5:377-86.

  4. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis. 2002;35:197-200.

  5. Clarithromycin Aurobindo (clarithromycin). Summary of Product Characteristics. Swedish Medical Products Agency. [updated 2021-11-30, cited 2021-02-09]

  6. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.

  7. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.]

  1. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C et al. Worldwide H pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010;19:409-14.
  2. Bluemel B, Goelz H, Goldmann B, Grüger J, Hamel H, Loley K et al. Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018. Clin Microbiol Infect. 2020;26(2):235-239.
  3. Coeman M, van Durme Y, Bauters F, Deschepper E, Demedts I, Smeets P et al. Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study. Ther Adv Respir Dis. 2011;5:377-86.
  4. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis. 2002;35:197-200.
  5. Clarithromycin Aurobindo (clarithromycin). Summary of Product Characteristics. Swedish Medical Products Agency. [updated 2021-11-30, cited 2021-02-09]
  6. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.
  7. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.]
A A
A A

Esomeprazol

Esomeprazol

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - NEXIUM (esomeprazole) [updated 2001-02-20].

  2. NEXIUM (esomeprazole). Summary of Product Characteristics. European Medicines Agency (EMA); 2014.

  3. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50:222-39.

  4. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.

  5. Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40:411-26.

  6. Labenz J, Armstrong D, Zetterstrand S, Eklund S, Leodolter A. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study. Aliment Pharmacol Ther. 2009;29:959-66.

  7. Helgadóttir H, Metz DC, Yang YX, Rhim AD, Björnsson ES. The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin. Dig Liver Dis. 2014;46:125-30.

  8. Helgadóttir H, Metz DC, Lund SH, Gizurarson S, Jacobsen EI, Asgeirsdóttir GA et al. Study of Gender Differences in Proton Pump Inhibitor Dose Requirements for GERD: A Double-Blind Randomized Trial. J Clin Gastroenterol. 2017;51(6):486-493.

  9. Biverkningar vid behandling med protonpumpshämmare (in Swedish). Janusinfo [www]. [updated 2022-09-20, cited 2023-05-22].

  10. Bose S, Guyer A, Long A, Banerji A. Evaluation and management of hypersensitivity to proton pump inhibitors. Ann Allergy Asthma Immunol. 2013;111:452-7.

  11. Laine K, Tybring G, Bertilsson L. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther. 2000;68:151-9.

  12. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  1. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - NEXIUM (esomeprazole) [updated 2001-02-20].
  2. NEXIUM (esomeprazole). Summary of Product Characteristics. European Medicines Agency (EMA); 2014.
  3. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50:222-39.
  4. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
  5. Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40:411-26.
  6. Labenz J, Armstrong D, Zetterstrand S, Eklund S, Leodolter A. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study. Aliment Pharmacol Ther. 2009;29:959-66.
  7. Helgadóttir H, Metz DC, Yang YX, Rhim AD, Björnsson ES. The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin. Dig Liver Dis. 2014;46:125-30.
  8. Helgadóttir H, Metz DC, Lund SH, Gizurarson S, Jacobsen EI, Asgeirsdóttir GA et al. Study of Gender Differences in Proton Pump Inhibitor Dose Requirements for GERD: A Double-Blind Randomized Trial. J Clin Gastroenterol. 2017;51(6):486-493.
  9. Biverkningar vid behandling med protonpumpshämmare (in Swedish). Janusinfo [www]. [updated 2022-09-20, cited 2023-05-22].
  10. Bose S, Guyer A, Long A, Banerji A. Evaluation and management of hypersensitivity to proton pump inhibitors. Ann Allergy Asthma Immunol. 2013;111:452-7.
  11. Laine K, Tybring G, Bertilsson L. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther. 2000;68:151-9.
  12. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]